Marshall Wace LLP Sells 347,915 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Marshall Wace LLP trimmed its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 71.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 138,111 shares of the company's stock after selling 347,915 shares during the quarter. Marshall Wace LLP owned approximately 0.07% of Taysha Gene Therapies worth $239,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Cibc World Markets Corp acquired a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $28,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $31,000. AXQ Capital LP acquired a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $39,000. Mariner LLC lifted its holdings in Taysha Gene Therapies by 337.5% in the 4th quarter. Mariner LLC now owns 58,342 shares of the company's stock worth $101,000 after purchasing an additional 45,006 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in Taysha Gene Therapies by 110.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company's stock worth $102,000 after purchasing an additional 31,000 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Chardan Capital reiterated a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. JMP Securities reiterated a "market outperform" rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA traded up $0.03 on Friday, reaching $2.13. 2,133,951 shares of the stock traded hands, compared to its average volume of 2,815,250. The firm has a market cap of $436.77 million, a price-to-earnings ratio of 3.38 and a beta of 0.90. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $4.32. The stock's 50-day moving average price is $1.65 and its 200-day moving average price is $1.81.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $2.02 million for the quarter, compared to analysts' expectations of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. Equities analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.